Literature DB >> 16476101

Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?

C Söderberg-Nauclér1.   

Abstract

Human cytomegalovirus (HCMV) is a herpes virus that infects and is carried by 70-100% of the world's population. During its evolution, this virus has developed mechanisms that allow it to survive in an immunocompetent host. For many years, HCMV was not considered to be a major human pathogen, as it appeared to cause only rare cases of HCMV inclusion disease in neonates. However, HCMV is poorly adapted for survival in the immunosuppressed host and has emerged as an important human pathogen in AIDS patients and in patients undergoing immunosuppressive therapy following organ or bone marrow transplantation. HCMV-mediated disease in such patients has highlighted the possible role of this virus in the development of other diseases, in particular inflammatory diseases such as vascular diseases, autoimmune diseases and, more recently, with certain forms of cancers. Current research is focused on determining whether HCMV plays a causative role in these diseases or is merely an epiphenomenon of inflammation. Inflammation plays a central role in the pathogenesis of HCMV. This virus has developed a number of mechanisms that enable it to hide from the cells of the immune system and, at the same time, reactivation of a latent infection requires immune activation. Numerous products of the HCMV genome are devoted to control central functions of the innate and adaptive immune responses. By influencing the regulation of various cellular processes including the cell cycle, apoptosis and migration as well as tumour invasiveness and angiogenesis, HCMV may participate in disease development. Thus, the various drugs now available for treatment of HCMV disease (e.g. ganciclovir, acyclovir and foscarnet), may also prove to be useful in the treatment of other, more widespread diseases.

Entities:  

Mesh:

Year:  2006        PMID: 16476101     DOI: 10.1111/j.1365-2796.2006.01618.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  130 in total

1.  Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up.

Authors:  Eric T Roberts; Mary N Haan; Jennifer Beam Dowd; Allison E Aiello
Journal:  Am J Epidemiol       Date:  2010-07-21       Impact factor: 4.897

Review 2.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

Review 3.  Role of tegument proteins in herpesvirus assembly and egress.

Authors:  Haitao Guo; Sheng Shen; Lili Wang; Hongyu Deng
Journal:  Protein Cell       Date:  2010-12-10       Impact factor: 14.870

Review 4.  Self or nonself? That is the question: sensing of cytomegalovirus infection by innate immune receptors.

Authors:  Michal Pyzik; Eve-Marie Gendron-Pontbriand; Nassima Fodil-Cornu; Silvia M Vidal
Journal:  Mamm Genome       Date:  2010-09-30       Impact factor: 2.957

Review 5.  The role of cytomegalovirus in angiogenesis.

Authors:  Patrizia Caposio; Susan L Orloff; Daniel N Streblow
Journal:  Virus Res       Date:  2010-10-01       Impact factor: 3.303

6.  Consensus on the role of human cytomegalovirus in glioblastoma.

Authors:  Kristine Dziurzynski; Susan M Chang; Amy B Heimberger; Robert F Kalejta; Stuart R McGregor Dallas; Martine Smit; Liliana Soroceanu; Charles S Cobbs
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

7.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

8.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

9.  Accurate identification of paraprotein antigen targets by epitope reconstruction.

Authors:  Seshi R Sompuram; Gerassimos Bastas; Kodela Vani; Steven A Bogen
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

10.  An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.

Authors:  Mark R Schleiss; Ryan Buus; K Yeon Choi; Alistair McGregor
Journal:  Future Virol       Date:  2013-12-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.